Turkish Academy of Sciences

Treprostinil (TRP) is a potent vasodilator used in thetreatmentof pulmonary arterial hypertension (PAH). The development of a rapid,sensitive, and selective electrochemical detection method for TRPis crucial for therapeutic monitoring and quality control. In thisstudy, we present a novel electrochemical sensor for TRP based onNiPB@Cu/Cu2O/GCE. The NiPB@Cu/Cu2O/GCE sensorexhibits excellent sensitivity and selectivity, enabling reliablequantification of TRP in biological and pharmaceutical samples. Thenanomaterial used in the sensor was characterized using field emissionscanning electron microscopy (FE-SEM), scanning transmission electronmicroscopy (STEM), X-ray diffraction (XRD), and Fourier transforminfrared spectroscopy (FTIR) to confirm its structural and morphologicalproperties. The developed sensor demonstrated a wide linear range,low detection limit, and high reproducibility, making it a promisingtool for clinical and pharmaceutical applications. This study providesa significant advancement in the electrochemical analysis of TRP,paving the way for further applications in drug monitoring and biomedicalresearch.

Afatinib (AFA), apowerful tyrosine kinase inhibitor, is an FDA-approved drug used totreat advanced nonsmall cell lung cancer (NSCLC) with certain EGFRmutations. As the first irreversible EGFR inhibitor approved for thetreatment of lung cancer, it plays a key role in blocking EGFR signaling,making it a significant therapy in targeted cancer treatment. Thisstudy presents a pioneering electrochemical approach for determiningAFA, a clinically significant anticancer agent, utilizing a novelsensor based on a trimetallic nanocomposite, silver–copper–aluminumlayered double hydroxide (AgCuAl-LDH). The sensor was fabricated througha facile, cost-effective hydrothermal synthesis method, resultingin a robust and highly conductive nanomaterial. Structural and morphologicalcharacterization via X-ray diffraction (XRD) and scanning electronmicroscopy (SEM) confirmed the successful formation of the nanocompositewith desirable crystalline and surface properties. Electrochemicalevaluation of AFA was conducted using cyclic voltammetry (CV) anddifferential pulse voltammetry (DPV), where the sensor exhibited asignificantly enhanced response. Electrochemical impedance spectroscopy(EIS) further validated the superior electrochemical performance ofthe sensor, showing reduced charge transfer resistance and elevatedconductivity. The proposed sensor demonstrated outstanding analyticalperformance with a high sensitivity of 1.65 μA·μM–1·cm–2, a wide linear detectionrange from 0.02 to 13.1 μM, and an impressively low detectionlimit of 2.99 nM. Importantly, the sensor was successfully appliedto real pharmaceutical formulations and biological samples, confirmingits practical utility in clinical and quality control settings. Thiswork marks the first electrochemical detection strategy for Afatinib,filling a critical gap in analytical methodologies and paving theway for advanced, efficient, and accessible sensing platforms in oncologydrug monitoring.